GlassScriptPhysician profile
Alice Luu
NPI 1932831955
$1,115.64
in general payments reported to CMS, 2019-2025
19 companies · $493 in 2025
The $493 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $323 · 2024: $300 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $168.43 | 2024-2025 | Fasenra, Tezspire |
| Penumbra, INC. | $144.45 | 2023 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $131.63 | 2024-2025 | |
| Abbvie INC. | $117.31 | 2025 | |
| La Jolla Pharmaceutical Company | $115.92 | 2025 | Giapreza |
| Olympus America INC. | $103.41 | 2024 | Spiration Valve System |
| Silk Road Medical, INC. | $96.97 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Pulmonx Corporation | $28.26 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Radius Health, INC. | $24.73 | 2023 | Tymlos |
| Alexion Pharmaceuticals, INC. | $23.45 | 2023 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $21.82 | 2025 | Eliquis |
| Viatris Specialty LLC | $21.00 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $20.12 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.11 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.71 | 2023 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.53 | 2024 | Winrevair |
| Takeda Pharmaceuticals U.S.A., INC. | $15.20 | 2025 | Glassia |
| Gilead Sciences, INC. | $15.06 | 2023 | |
| Verona Pharma, INC. | $13.53 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.